{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:27:53Z","timestamp":1776680873131,"version":"3.51.2"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":151,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2022.100676","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T01:49:23Z","timestamp":1654220963000},"page":"100676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review"],"prefix":"10.1016","volume":"96","author":[{"given":"Seyedeh Fatemeh","family":"Sadatmadani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Malakoutikhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Mohaghegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadsaleh","family":"Peikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Saboktakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.curtheres.2022.100676_bib0001","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdv.12172","article-title":"Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience","volume":"27","author":"Brazzelli","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"12","key":"10.1016\/j.curtheres.2022.100676_bib0002","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous adverse events of targeted therapies for hematolymphoid malignancies","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100676_bib0003","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12153","article-title":"Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment","volume":"91","author":"Nagai","year":"2013","journal-title":"European Journal of Haematology"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100676_bib0004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4103\/0378-6323.152311","article-title":"Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate","volume":"81","author":"Kaur","year":"2015","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"229","key":"10.1016\/j.curtheres.2022.100676_bib0005","first-page":"2","article-title":"Development of Psoriasis Vulgaris in a Chronic Myeloid Leukemia Patient on Second-Generation Tyrosine Kinase Inhibitor Therapy","volume":"5","author":"Thekkudan","year":"2017","journal-title":"J Leuk"},{"key":"10.1016\/j.curtheres.2022.100676_bib0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.190119","article-title":"The genetics of psoriasis and psoriatic arthritis","volume":"95","author":"O'Rielly","year":"2019","journal-title":"The Journal of Rheumatology Supplement"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100676_bib0007","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/0019-5154.156367","article-title":"Elephantine psoriasis with papillomatosis and alternating hypogranulosis and hypergranulosis","volume":"60","author":"Koley","year":"2015","journal-title":"Indian Journal of Dermatology"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100676_bib0008","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000353398","article-title":"Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature","volume":"227","author":"Mattozzi","year":"2013","journal-title":"Dermatology"},{"issue":"12","key":"10.1016\/j.curtheres.2022.100676_bib0009","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-4632.2010.04570.x","article-title":"The role of drugs in the induction and\/or exacerbation of psoriasis","volume":"49","author":"Basavaraj","year":"2010","journal-title":"International journal of dermatology"},{"key":"10.1016\/j.curtheres.2022.100676_bib0010","first-page":"87","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckland, NZ)"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100676_bib0011","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"AMITAY-LAISH","year":"2011","journal-title":"Dermatologic therapy"},{"issue":"5b","key":"10.1016\/j.curtheres.2022.100676_bib0012","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","article-title":"Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling","volume":"12","author":"Chen","year":"2008","journal-title":"Journal of cellular and molecular medicine"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100676_bib0013","first-page":"1133","article-title":"Imatinib impairs the proliferation and function of CD4+ CD25+ regulatory T cells in a dose-dependent manner","volume":"31","author":"Chen","year":"2007","journal-title":"International journal of oncology"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100676_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-22","article-title":"Effects of nilotinib on regulatory T cells: the dose matters","volume":"9","author":"Fei","year":"2010","journal-title":"Molecular cancer"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100676_bib0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2002.497217.x","article-title":"Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour","volume":"147","author":"Miyagawa","year":"2002","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100676_bib0016","article-title":"Tyrosine kinase inhibitors in dermatology: A systemic review","volume":"6","author":"Naik","year":"2021","journal-title":"J Dermatology and Dermatitis"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:59:34Z","timestamp":1757897974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X22000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":16,"alternative-id":["S0011393X22000157"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100676","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100676"}}